. Author manuscript; available in PMC: 2022 Jul 15.

Published in final edited form as: J Heart Lung Transplant. 2021 Aug 25;40(12):1641–1648. doi: 10.1016/j.healun.2021.08.005

Table 4.

Sensitivity Analysis with Competing Risk Regression Analyses Performed with Different Assumptions for 44 Patients with a Final Waitlist Outcome of “Other”

	Obstructive lung disease – Group A		Pulmonary arterial hypertension – Group B		Cystic fibrosis – Group C		Interstitial lung disease – Group D
	SHR transplant^a	SHR death/removal^a	SHR transplant^a	SHR death/removal^a	SHR transplant^a	SHR death/removal^a	SHR transplant^a	SHR death/removal^a
Assuming all “other” outcome patients died or were removed	1.89 p = 0.003	0.46 p = 0.020	1	1	1.84 p < 0.001	0.55 p = 0.007	1.73 p = 0.001	0.61 p < 0.001
Excluding all “other” outcome patients from the analysis	1.53 p = 0.045	0.57 p = 0.107	1	1	1.45 p = 0.025	0.75 p = 0.229	1.42 p = 0.016	0.76 p = 0.146

Abbreviation: SHR, sub-distribution hazard ratio.

The bold values are statistically significant bases on the statistical analysis used (i.e. the confidence interval does not cross 1, and the p-value was <0.05).

Adjusted for initial age, ABO blood type, height, and listing only for double lung transplant.